Recently, a research team led by Professor Yong Tao and Professor Wei Wei from Beijing Chaoyang Hospital, Capital Medical University, and the National Key Laboratory of Biopharmaceutical Preparation and Delivery at the Institute of Process Engineering, Chinese Academy of Sciences, published a study titled "Catalytic neural stem cell exosomes for multi-stage targeting and synergistical therapy of retinal ischemia-reperfusion injury" in Cell Reports Medicine. The team developed engineered neural stem cell exosomes (CataKNexo) that can precisely target the fundus and exert dual effects of antioxidant damage and neuroprotection. This provides a new approach for the treatment of retinal ischemia-reperfusion injury.
Professor Yong Tao is one of the first batch of Young Cooperative Talents appointed to the CIMR's Organized Research Projects.
Fulltext link: https://pubmed.ncbi.nlm.nih.gov/40239632/
Young Cooperative Talent
Yong Tao
Chief Physician, Professor, and Doctoral Supervisor. Director of the Department of Ophthalmology at Beijing Chaoyang Hospital, Capital Medical University.
With 20 years of experience in frontline ophthalmological clinical work, he is dedicated to the precise diagnosis and treatment of retinal diseases and uveitis. His major academic achievements include:
1. Development of an Integrated Micro-Volume Ocular Fluid Rapid Detection System: This system has been widely applied and has promoted the development of precise diagnostic paradigms for eye diseases. It breaks the monopoly of QUIDEL Corporation (USA) and Hitachi Chemical Company (Japan), and has been included in the National Health Technology Promotion and Application Information Service Platform's technology reserve. The system has obtained a Class II medical device registration certificate, EU CE certification, US FDA certification, and market access in Colombia.
2. Pioneering Multi-Level Directed Drug Delivery to the Retina: He proposed and experimentally verified the concept of multi-level directed drug delivery to the retina, achieving precise delivery of drugs to different sublayers of the retina.
3. Innovative Development of New Strategies for Treating Retinal Diseases: He has developed several novel strategies for treating retinal diseases, including spatiotemporal coupling and biomimetic controlled release, providing directions for the precise, long-lasting, and multi-effect control of retinal inflammation in clinical settings.
He has published 57 SCI papers and 26 papers in core Chinese journals, and holds 3 national patents. He has received numerous honors, including the title of "Top 100 Talents" in Xicheng District, the "Exploration Star" award in the second session of the "Life Heroes" in the medical and health sector, and the title of "Top 10 Outstanding Young Doctors in the Capital" in 2015.
Project Title:
Development of Targeted Oligonucleotide Drug Systems for Treating Retinal Diseases and Non-Invasive Drug Delivery Strategies (Sub-Topic 1: Molecular Mechanisms of Common Retinal Pathological Changes, Research on the Effects of Oligonucleotide Drugs, and Series of Evaluations)
Project Brief Introduction:
The project focuses on precise treatment of vitreoretinal diseases, including three aspects of work: (1) in-depth mechanism research to explore new targets for the treatment of vitreoretinal diseases; (2) New drug delivery methods targeting different cells in the fundus of the eye; (3) A new strategy for the treatment of vitreoretinal diseases that is multi-effective, sustained releasing, and intelligent.
10 Xitoutiao, Youanmen Wai, Fengtai District, Beijing 100069, China
010-86738999
cimr@cimrbj.ac.cn
中文
